|
Chemo-Immuno-Gene
Therapy for Malignant Brain Tumors
Translating encouraging preliminary results of novel
immuno-gene therapy, in combination with a novel molecular
genetic chemotherapy, into a new treatment for intracerebral
breast cancer. 2003 NeuroGrant Recipient
Immuno-Gene Therapy
for Malignant Brain Tumors
Translating encouraging preliminary results of novel
molecular genetic immunotherapy into the clinical setting.
Determining the safety and efficacy of treating human intracerebral
malignant tumors using genetically modified IL-2 secreting
cells as a tumor vaccine.
Pituitary Patient Support Group
Formation of a Pituitary
Patient Support Group to serve as a clearinghouse of information
for treatment options, as well as a source of support for
those dealing with the emotional aspects of such illnesses. 2004 NeuroGrant Recipient
Immuno-Gene Therapy for Malignant Brain Tumors: A Clinical
Trial
Determine the safety and efficacy of treating human intracerebral
malignant tumors using genetically modified IL-2 secreting
cells transduced with the patient’s DNA, as a tumor vaccine. 2006 NeuroGrant Recipient
Trait vs. State Anxiety as a Predictor as a Predictor on Post Operative Health Outcomes
To investigate the influence that both state and trait anxiety has on physiological markers of stress and to subsequent post-surgical related outcomes. 2006 NeuroGrant Recipient
Managing Brain Metastases in Patients with Advanced Breast
Cancer (fig. 4)
White paper funded by generous grants from HER2 Support Group
and Elekta Inc. describing the treatment options for patients
with metastatic breast cancer.
Early Detection of Brain Metastases from Advanced Breast
Cancer Through Education and Screening (fig. 5)
A two part project which will: 1) provide educational information
to breast cancer patients regarding the prevalence of metastases
to the brain, available treatments, and the importance of
brain scans and early detection and 2) undertake a research
project which will examine the role of early screening for
brain metastases arising from breast cancer. 2006 NeuroGrant
Recipient
Childhood Cancer Associated Brain Disorders: Inflammatory Mediators as Therapeutic Targets (fig. 6)
Evaluate the role of pro-inflammatory and anti-inflammatory cytokines in OMS; to determine the effects of immunotherapy on the cytokine profile; an correlate cytokine abnormalities with clinical variables such as disease severity. 2006 NeuroGrant Recipient
Leukocyte Chemokine Receptor Expression in Immune-Mediated Brain Injury
To determine the expression of chemokine receptors for on the immune cell type the chemokine recruits to inflamed brain. 2007 NeuroGrant Recipient
Post-Operative Health Care Coordinator Project
To provide newly diagnosed brain tumor patients an opportunity to speak with a health care coordinator 7 and 20 day post-discharge. They will be asked questions designed to quickly assess their functioning that will dovetail with an assessment tool provided at discharge which will enable patients to identify and communicate subtle changes in their functioning that will allow for patient centered solutions. 2007 NeuroGrant Recipient
Somatic Localization Using the Placing Test
Determining if the Placing Test can be used to screen
brain tumor patients for complications or regrowth. 2003
NeuroGrant Recipient
|
